•
AL
ALMS
Alumis Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
3.33B
Volume
96.17K
52W High
$27.20
52W Low
$2.76
Open
$0.00
Prev Close
$26.68
Day Range
0.00 - 0.00
About Alumis Inc. Common Stock
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
Latest News
Alumis Announces Pricing of Upsized Public Offering of Common Stock
GlobeNewswire Inc.•Jan 8
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib
The Motley Fool•Jan 6
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis
GlobeNewswire Inc.•Jan 5
Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
GlobeNewswire Inc.•Oct 16
Alumis Misses Q2 Revenue as Costs Jump
The Motley Fool•Aug 13
Alumis Completes Merger with ACELYRIN
Benzinga•May 21
Alumis Stockholders Approve Merger with ACELYRIN
GlobeNewswire Inc.•May 13
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
GlobeNewswire Inc.•May 13